Dr. Shaji Kumar on MRD in Multiple Myeloma

Video

Shaji Kumar, MD, professor of Medicine at Mayo Clinic, discusses how minimal residual disease (MRD) testing has evolved in multiple myeloma.

Shaji Kumar, MD, professor of Medicine at Mayo Clinic, discusses how minimal residual disease (MRD) testing has evolved in multiple myeloma.

The concept of MRD testing has been around for a long time in hematological malignancies, mainly in chronic myeloid leukemia (CLL), which has a very defined disease-related genetic change, says Kumar. However, it has been different in other diseases that are more heterogeneous, he says.

Now more effective treatment combinations are available that can produce very high response rates in multiple myeloma. The current response criteria do not adequately provide the ability to understand and measure those deep responses and compare them between trials, says Kumar.

To clarify best practices, the International Myeloma Working Group recently released updated consensus criteria for response and MRD assessment in multiple myeloma.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD